Skip to main content

CJC-1295 (no DAC) vs Sermorelin

Both CJC-1295 (no DAC) and Sermorelin are used for growth-hormone and anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.

CJC-1295 (no DAC)

Evidence B

Modified Growth Hormone Releasing Factor 1-29

A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.

View full CJC-1295 (no DAC) profile →

Sermorelin

Evidence B+

Sermorelin Acetate (GHRH 1-29)

The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.

View full Sermorelin profile →

Side-by-Side

AttributeCJC-1295 (no DAC)Sermorelin
Evidence GradeBB+
FDA StatusNot FDA-approved — Category 1 (compounding allowed)FDA-approved (1990) for pediatric growth hormone deficiency; off-label adult use via compounding pharmacies
Typical Dose100–300 mcg before bed (subcutaneous)200–500 mcg before bed (subcutaneous)
Clinics Indexed156220
Categoriesgrowth-hormone, anti-aging, recoverygrowth-hormone, anti-aging

Key reported benefits — CJC-1295 (no DAC)

  • Growth hormone release
  • Fat loss
  • Improved sleep
  • Muscle recovery

Key reported benefits — Sermorelin

  • Natural GH release
  • Improved sleep
  • Lean body mass
  • Recovery

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons